KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial.

Mazen Noureddin, Mary Rinella, Rebecca Taub, Dominic Labriola, Raul C Camacho, Naim Alkhouri, Rohit Loomba, Meena B Bansal

Aliment Pharmacol Ther 62(11-12) 1089-1099

PMID41127972
PMCIDPMC12646629
DOI10.1111/apt.70382
发表日期2025-10-23
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:森林图/亚组分析图;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。
摘要

摘要

BACKGROUND: MAESTRO-NASH, a randomised, double-blind, placebo-controlled, 54-month phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed metabolic-dysfunction associated steatohepatitis (MASH) and liver fibrosis achieved primary endpoints of MASH resolution with no worsening of fibrosis, and ≥ 1-stage improvement in fibrosis with no worsening of MASH at 52-weeks. AIMS: The effects of resmetirom (80 or 100 mg) versus placebo were evaluated on Week 52 histological and biomarker endpoints in relation to background treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i), GLP-1 receptor agonists (GLP-1 RA), and/or ≥ 5% weight loss at Week 52. METHODS: At baseline, 13%-17% of patients (all with type 2 diabetes mellitus [T2DM]) were on stable GLP-1 RA or SGLT2i therapy. Changes in liver histology, MRI-proton density fat fraction (MRI-PDFF), and liver stiffness were examined after 52 weeks of treatment. RESULTS: No weight loss above baseline occurred with GLP-1 RA or SGLT2i therapy. SGLT2 and GLP-1 RA treated patients showed similar rates of MASH resolution and fibrosis improvement in combination with resmetirom as patients not on these therapies. Resmetirom-treated patients (100 mg) with weight loss (≥ 5%) compared with those with weight loss < 5% had higher rates of MASH resolution (56.6% vs. 33.8%), fibrosis improvement (40.6% vs. 31.5%), MRI-PDFF reduction (-69% vs. -46%), and liver stiffness reduction after 52 weeks of treatment (-4.6 kPa vs. -2.3 kPa). CONCLUSIONS: The efficacy of resmetirom on multiple MASH endpoints was not impacted by background SGLT2i or GLP-1 RA treatment. Weight loss (≥ 5%) enhanced the efficacy of resmetirom. TRIAL REGISTRATION: MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 MASH resolution with no worsening of fibrosis and fibrosis improvement (reduction by at least one stage with no worsening of the MASH) in T2DM patients in presence or absence of GLP‐1 RA (A and B) or SGLT2i (C and D). Pbo, placebo; Res, resmetirom.
非 KM Figure
FIGURE 2FIGURE 2 Relative (median) hepatic fat reduction at Week 52 in various subgroups of patients on resmetirom (80 or 100 mg) or placebo. See Table S4 for Ns.
非 KM Figure
FIGURE 3FIGURE 3 MASH resolution with no worsening of fibrosis and fibrosis improvement (reduction by at least one stage with no worsening of MASH) in patients with (A) or without (B) ≥ 5% weight loss, and mediation analysis: Odds ratios (OR) with 95% confidence intervals for the total effect of resmetirom versus placebo, as well as the direct treatment effect and the indirect effect mediated through the percent change in weight at Week 52 on both MASH resolution and fibrosis improvement (C). CI, confidence interval; OR, odds ratio; Pbo, placebo.
非 KM Figure
FIGURE 4FIGURE 4 Relative (median) hepatic fat reduction at weeks 16 and 52 and percentage of patients achieving 30% reduction in hepatic fat in patients on resmetirom (80 or 100 mg) or placebo with ≥ 5% weight loss (A and B) or < 5% weight loss (C and D) at Week 52. Pbo, placebo; W, week.
非 KM Figure
FIGURE 5FIGURE 5 Absolute Fibroscan VCTE reduction (A) and percentage of patients achieving a ≥ 25% improvement or worsening in VCTE (B) in patients with ≥ 5% or < 5% weight loss at Week 52 according to treatment.
非 KM Figure